Insulin Glargine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Insulin Glargine: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin glargine is a long-acting basal insulin analog, originally used to treat type 1 and type 2 diabetes mellitus. The TxGNN model predicts it may be effective for autoimmune oophoritis, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis (from the knowledge graph; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, insulin glargine is a long-acting basal insulin analog that acts on the insulin receptor to lower blood glucose. Its efficacy in diabetes is well established.
For autoimmune oophoritis, no direct mechanistic link has been established. The high score is a graph-based prediction only. The most plausible connection is indirect: autoimmune ovarian disease often appears alongside other autoimmune endocrine conditions, including type 1 diabetes. This is a shared-comorbidity association, not evidence that insulin glargine would treat the ovarian condition. Any therapeutic rationale would be speculative.
Other top-ranked predictions show similar patterns. Several (stiff person syndrome, thiamine-responsive dysfunction syndrome) reflect comorbid diabetes. Others (localized lipodystrophies) likely reflect a known adverse effect of insulin injections, which is a harm signal rather than a benefit. Pancreatic agenesis, rank 6, is the only one where insulin replacement is mechanistically rational, but that is hormone replacement for the resulting diabetes, not true repurposing.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16009P | Semglee Solution for Injection in a Prefilled Pen 100U/ml | Injection, solution | Not available |
| SIN15138P | Toujeo SoloStar 300 units/ml solution for injection in a pre-filled pen | Injection, solution | Not available |
| SIN11934P | Lantus 100 Units/ml Solution for injection in a vial | Injection | Not available |
| SIN13426P | Lantus SoloStar 100 Units/ml Solution for injection in a pre-filled pen | Injection, solution | Not available |
| SIN15540P | Soliqua Solution for Injection in a Pre-filled Pen 100 units/ml + 50 mcg/ml | Injection, solution | Not available |
One further registration, SIN15542P (Soliqua 100 units/ml + 33 mcg/ml pre-filled pen), is also valid. All six registrations are single-ingredient entries and none is cancelled.
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction database, and the first 20 were reviewed. Most are moderate, with a few minor. Examples:
- Other glucose-lowering agents: metformin, pioglitazone, alogliptin, albiglutide
- Sympathomimetics and beta-agonists: epinephrine, phenylephrine, pseudoephedrine, salbutamol, formoterol
- Corticosteroids: hydrocortisone
- Hormonal agents: estradiol, ethinylestradiol
- Others: acebutolol, acetazolamide, hydrochlorothiazide, doxycycline, ethanol, alpelisib
These can raise or lower blood glucose or mask hypoglycaemia symptoms, so glucose monitoring is important.
- Injection-site effects: Localized lipodystrophy is a recognized effect of repeated subcutaneous insulin injection at the same site.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for autoimmune oophoritis is supported only by the model score, with no clinical trials, no literature, and no established mechanism. Plausible associations are indirect, through shared autoimmune comorbidity with type 1 diabetes.
To proceed, the following is needed:
- Mechanism of action data for insulin glargine and a defined biological rationale for ovarian autoimmunity
- Any preclinical or clinical evidence in autoimmune oophoritis
- Package insert warnings and contraindications from the Singapore regulator, and approved indication text for the registered products
- Route and dosing compatibility assessment for the proposed use
- Separate review of rank 6 (pancreatic agenesis) as replacement therapy, since it is the most clinically coherent of the top predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.